These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9580627)

  • 1. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization.
    Bannon AW; Decker MW; Curzon P; Buckley MJ; Kim DJ; Radek RJ; Lynch JK; Wasicak JT; Lin NH; Arnold WH; Holladay MW; Williams M; Arneric SP
    J Pharmacol Exp Ther; 1998 May; 285(2):787-94. PubMed ID: 9580627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice.
    Decker MW; Bannon AW; Buckley MJ; Kim DJ; Holladay MW; Ryther KB; Lin NH; Wasicak JT; Williams M; Arneric SP
    Eur J Pharmacol; 1998 Apr; 346(1):23-33. PubMed ID: 9617748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat.
    Kowaluk EA; Mikusa J; Wismer CT; Zhu CZ; Schweitzer E; Lynch JJ; Lee CH; Jiang M; Bhagwat SS; Gomtsyan A; McKie J; Cox BF; Polakowski J; Reinhart G; Williams M; Jarvis MF
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1165-74. PubMed ID: 11082454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.
    Donnelly-Roberts DL; Puttfarcken PS; Kuntzweiler TA; Briggs CA; Anderson DJ; Campbell JE; Piattoni-Kaplan M; McKenna DG; Wasicak JT; Holladay MW; Williams M; Arneric SP
    J Pharmacol Exp Ther; 1998 May; 285(2):777-86. PubMed ID: 9580626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.
    Holladay MW; Wasicak JT; Lin NH; He Y; Ryther KB; Bannon AW; Buckley MJ; Kim DJ; Decker MW; Anderson DJ; Campbell JE; Kuntzweiler TA; Donnelly-Roberts DL; Piattoni-Kaplan M; Briggs CA; Williams M; Arneric SP
    J Med Chem; 1998 Feb; 41(4):407-12. PubMed ID: 9484491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model.
    Lynch JJ; Wade CL; Mikusa JP; Decker MW; Honore P
    Eur J Pharmacol; 2005 Feb; 509(1):43-8. PubMed ID: 15713428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphine and ABT-594 (a nicotinic acetylcholine agonist) exert centrally mediated antinociception in the rat cyclophosphamide cystitis model of visceral pain.
    Joshi SK; Mikusa JP; Weaver B; Honore P
    J Pain; 2008 Feb; 9(2):146-56. PubMed ID: 18088559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping brain activity following administration of a nicotinic acetylcholine receptor agonist, ABT-594, using functional magnetic resonance imaging in awake rats.
    Skoubis PD; Hradil V; Chin CL; Luo Y; Fox GB; McGaraughty S
    Neuroscience; 2006; 137(2):583-91. PubMed ID: 16289887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A-366833: a novel nicotinonitrile-substituted 3,6-diazabicyclo[3.2.0]-heptane alpha4beta2 nicotinic acetylcholine receptor selective agonist: Synthesis, analgesic efficacy and tolerability profile in animal models.
    Ji J; Bunnelle WH; Anderson DJ; Faltynek C; Dyhring T; Ahring PK; Rueter LE; Curzon P; Buckley MJ; Marsh KC; Kempf-Grote A; Meyer MD
    Biochem Pharmacol; 2007 Oct; 74(8):1253-62. PubMed ID: 17854775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats.
    Zhu CZ; Chin CL; Rustay NR; Zhong C; Mikusa J; Chandran P; Salyers A; Gomez E; Simler G; Lewis LG; Gauvin D; Baker S; Pai M; Tovcimak A; Brown J; Komater V; Fox GB; Decker MW; Jacobson PB; Gopalakrishnan M; Lee CH; Honore P
    Biochem Pharmacol; 2011 Oct; 82(8):967-76. PubMed ID: 21620806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
    Decker MW; Brioni JD; Sullivan JP; Buckley MJ; Radek RJ; Raszkiewicz JL; Kang CH; Kim DJ; Giardina WJ; Wasicak JT
    J Pharmacol Exp Ther; 1994 Jul; 270(1):319-28. PubMed ID: 7913497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antinociceptive and pharmacological effects of metanicotine, a selective nicotinic agonist.
    Damaj MI; Glassco W; Aceto MD; Martin BR
    J Pharmacol Exp Ther; 1999 Oct; 291(1):390-8. PubMed ID: 10490929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain.
    Nirogi R; Jabaris SL; Jayarajan P; Abraham R; Shanmuganathan D; Rasheed MA; Royapalley PK; Goura V
    Eur J Pharmacol; 2011 Oct; 668(1-2):155-62. PubMed ID: 21756895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats.
    Boyce S; Webb JK; Shepheard SL; Russell MGN; Hill RG; Rupniak NMJ
    Pain; 2000 Apr; 85(3):443-450. PubMed ID: 10781917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
    Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
    J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences between the antinociceptive effects of the cholinergic channel activators A-85380 and (+/-)-epibatidine in rats.
    Curzon P; Nikkel AL; Bannon AW; Arneric SP; Decker MW
    J Pharmacol Exp Ther; 1998 Dec; 287(3):847-53. PubMed ID: 9864263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse.
    Jarvis MF; Yu H; Kohlhaas K; Alexander K; Lee CH; Jiang M; Bhagwat SS; Williams M; Kowaluk EA
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1156-64. PubMed ID: 11082453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective potentiation of gabapentin-mediated antinociception in the rat formalin test by the nicotinic acetylcholine receptor agonist ABT-594.
    Munro G; Dyhr H; Grunnet M
    Neuropharmacology; 2010 Sep; 59(3):208-17. PubMed ID: 20562022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α4β2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of α4β2 nAChR agonists in pain.
    Lee CH; Zhu C; Malysz J; Campbell T; Shaughnessy T; Honore P; Polakowski J; Gopalakrishnan M
    Biochem Pharmacol; 2011 Oct; 82(8):959-66. PubMed ID: 21763685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antinociceptive effects of centrally administered CDP-choline on acute pain models in rats: the involvement of cholinergic system.
    Hamurtekin E; Gurun MS
    Brain Res; 2006 Oct; 1117(1):92-100. PubMed ID: 16942753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.